Assure (IONM) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 10, 2022
Document and Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Entity File Number	001-40785
Entity Registrant Name	ASSURE HOLDINGS CORP.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	82-2726719
Entity Address, State or Province	CO
Entity Address, Address Line One	7887 E. Belleview Ave., Suite 500
Entity Address, City or Town	Denver
Entity Address, Postal Zip Code	80111
City Area Code	720
Local Phone Number	287-3093
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	IONM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		18,512,605
Entity Central Index Key	0001798270
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash	$ 3,798	$ 4,020
Accounts receivable, net	20,860	27,810
Income tax receivable	157	136
Other current assets	217	151
Due from MSAs	6,602	5,886
Total current assets	31,634	38,003
Equity method investments	474	525
Fixed assets	35	85
Operating lease right of use asset, net	725	956
Finance lease right of use asset, net	469	743
Deferred tax asset, net	2,536
Intangibles, net	3,311	3,649
Goodwill	4,448	4,448
Total assets	43,632	48,409
Current liabilities
Accounts payable and accrued liabilities	2,585	2,194
Current portion of debt		515
Current portion of lease liability	622	702
Current portion of acquisition liability	306	306
Other current liabilities	133
Total current liabilities	3,646	3,717
Lease liability, net of current portion	1,102	1,482
Debt, net of current portion	12,628	13,169
Acquisition liability	255	459
Fair value of stock option liability		25
Deferred tax liability , net		601
Total liabilities	17,631	19,453
Commitments and contingencies (Note 8)
SHAREHOLDERS' EQUITY
Common stock: $0.001 par value; 180,000,000 shares authorized; 18,512,605 and 12,918,866 shares issued and outstanding, as of September 30, 2022, and December 31, 2021, respectively	19	13
Additional paid-in capital	49,044	43,387
Accumulated deficit	(23,062)	(14,444)
Total shareholders' equity	26,001	28,956
Total liabilities and shareholders' equity	$ 43,632	$ 48,409

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
CONDENSED CONSOLIDATED BALANCE SHEETS
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	180,000,000	180,000,000	900,000,000
Common stock, shares issued	18,512,605	12,918,866
Common stock, shares outstanding	18,512,605	12,918,866

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue
Revenue	$ 6,204	$ 8,546	$ 12,550	$ 19,533
Cost of revenues, excluding depreciation and amortization	3,685	4,254	11,564	9,956
Gross margin	2,519	4,292	986	9,577
Operating expenses
General and administrative	3,340	3,180	11,177	10,275
Sales and marketing	198	247	688	748
Depreciation and amortization	243	293	761	965
Total operating expenses	3,781	3,720	12,626	11,988
(Loss) income from operations	(1,262)	572	(11,640)	(2,411)
Other income (expenses)
Income from equity method investments	9	139	18	136
Gain on Paycheck Protection Program loan forgiveness			1,665
Other income (expense), net	(37)	(27)	29	(29)
Accretion expense	(170)	(171)	(511)	(386)
Interest expense, net	(471)	(264)	(1,317)	(500)
Total other expense	(669)	(323)	(116)	(779)
(Loss) income before income taxes	(1,931)	249	(11,756)	(3,190)
Income tax benefit (expense)	498	(158)	3,138	743
Net (loss) income	$ (1,433)	$ 91	$ (8,618)	$ (2,447)
(Loss) income per share
Basic	$ (0.09)	$ 0.01	$ (0.63)	$ (0.21)
Diluted	$ (0.09)	$ 0.01	$ (0.63)	$ (0.21)
Weighted average number of shares used in per share calculation - basic	15,220,948	11,838,032	13,686,686	11,528,371
Weighted average number of shares used in per share calculation - diluted	15,220,948	15,724,103	13,686,686	11,528,371
Technical services
Revenue
Revenue	$ 1,190	$ 4,421	$ 2,653	$ 11,649
Professional services
Revenue
Revenue	4,278	2,738	7,605	3,704
Other.
Revenue
Revenue	$ 736	$ 1,387	$ 2,292	$ 4,180

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net loss	$ (8,618)	$ (2,447)
Adjustments to reconcile net loss to net cash used in operating activities
Income from equity method investments	(18)	(136)
Stock-based compensation	464	818
Depreciation and amortization	408	599
Amortization of debt issuance costs	120	53
Provision for stock option fair value	(25)	24
Gain on Paycheck Protection Program loan	(1,665)
Accretion expense	511	386
Change in operating assets and liabilities
Accounts receivable, net	6,950	(5,723)
Prepaid expenses	(66)	177
Right of use assets	585	291
Accounts payable and accrued liabilities	391	(1,045)
Due from MSAs	(716)	(1,121)
Lease liability	(540)	(399)
Income taxes	(3,158)	(743)
Other assets and liabilities	117	(86)
Net cash used in operating activities	(5,260)	(9,352)
Cash flows from investing activities
Purchase of fixed assets	(26)
Net cash paid for acquisitions	(204)	(204)
Distributions received from equity method investments	69	312
Net cash provided by (used in) investing activities	(161)	108
Cash flows from financing activities
Proceeds from exercise of stock options	4	19
Proceeds from share issuance, net	5,195	832
Proceeds from Paycheck Protection Program loan		1,665
Proceeds from debenture		7,360
Repayment of short-term debt		(4,100)
Net cash provided by financing activities	5,199	5,776
Decrease in cash	(222)	(3,468)
Cash at beginning of period	4,020	4,386
Cash at end of period	3,798	918
Supplemental cash flow information
Interest paid	1,093	301
Supplemental non-cash flow information
Purchase of equipment with finance leases	$ 79	$ 431

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional paid-in capital	Accumulated deficit	Total
Beginning Balances at Dec. 31, 2020	$ 11	$ 30,886	$ (11,688)	$ 19,209
Beginning Balances (in shares) at Dec. 31, 2020	11,275,788
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		19		19
Exercise of stock options (in shares)	3,000
Share issuance, net	$ 1	3,105		3,106
Share issuance, net (in shares)	503,148
Stock-based compensation		818		818
Convertible debt converted into common shares		60		60
Convertible debt converted into common shares (in shares)	13,384
Equity component of debenture issuance		1,204		1,204
Settlement of performance share liability		2,293		2,293
Settlement of performance share liability (in shares)	43,968
Other (in shares)	15
Net income (loss)			(2,447)	(2,447)
Ending Balance at Sep. 30, 2021	$ 12	38,385	(14,135)	24,262
Ending Balance (in shares) at Sep. 30, 2021	11,839,304
Beginning Balances at Jun. 30, 2021	$ 12	38,136	(14,226)	23,922
Beginning Balances (in shares) at Jun. 30, 2021	11,833,431
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		19		19
Exercise of stock options (in shares)	3,000
Stock-based compensation		210		210
Convertible debt converted into common shares		20		20
Convertible debt converted into common shares (in shares)	2,858
Other (in shares)	15
Net income (loss)			91	91
Ending Balance at Sep. 30, 2021	$ 12	38,385	(14,135)	24,262
Ending Balance (in shares) at Sep. 30, 2021	11,839,304
Beginning Balances at Dec. 31, 2021	$ 13	43,387	(14,444)	28,956
Beginning Balances (in shares) at Dec. 31, 2021	12,918,866
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		4		4
Exercise of stock options (in shares)	800
Share issuance, net	$ 6	5,189		5,195
Share issuance, net (in shares)	5,576,087
Stock-based compensation		464		464
Stock-based compensation (in shares)	16,852
Net income (loss)			(8,618)	(8,618)
Ending Balance at Sep. 30, 2022	$ 19	49,044	(23,062)	26,001
Ending Balance (in shares) at Sep. 30, 2022	18,512,605
Beginning Balances at Jun. 30, 2022	$ 13	43,963	(21,629)	22,347
Beginning Balances (in shares) at Jun. 30, 2022	12,919,666
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share issuance, net	$ 6	5,189		5,195
Share issuance, net (in shares)	5,576,087
Stock-based compensation		(108)		(108)
Stock-based compensation (in shares)	16,852
Net income (loss)			(1,433)	(1,433)
Ending Balance at Sep. 30, 2022	$ 19	$ 49,044	$ (23,062)	$ 26,001
Ending Balance (in shares) at Sep. 30, 2022	18,512,605

NATURE OF OPERATIONS

NATURE OF OPERATIONS	9 Months Ended
	Sep. 30, 2022
NATURE OF OPERATIONS
NATURE OF OPERATIONS	1. ​ Assure Holdings Corp. (the “Company” or “Assure”), through its two wholly owned subsidiaries, Assure Neuromonitoring, LLC (“Assure Neuromonitoring”) and Assure Networks, LLC (“Assure Networks”), provides technical and professional intraoperative neuromonitoring (“IONM”) surgical support services for neurosurgery, spine, cardiovascular, orthopedic, ear, nose, and throat, and other surgical procedures that place the nervous system at risk. interoperative neurophysiologists (“INP”) electroencephalographic ( electromyography (“ Assure Networks performs similar support services as Assure Neuromonitoring except that these services are provided by employed or third party contracted neurologists or certified readers. The support service provided by the neurologist occurs at an offsite location at the same time and for the same surgery as the support services provided by the interoperative neurophysiologist. The Company was originally incorporated in Colorado on November 7, 2016. In conjunction with a reverse merger, the Company was redomiciled in Nevada on May 16, 2017. Neuromonitoring was formed on August 25, 2015, in Colorado and currently has multiple wholly owned subsidiaries. The Company’s services are sold in the United States, directly through the Company. Networks was formed on November 7, 2016, in Colorado and holds varying ownerships interests in numerous Provider Network Entities (“PEs”), which are professional IONM entities. These entities are accounted for under the equity method of accounting. Additionally, Networks manages other PEs that Networks does not have an ownership interest and charges those PEs a management fee. COVID The Company’s commitment to the health, well-being and peace of mind of our employees and the people we serve remains our focus as the pandemic environment evolves. We continue to leverage our resources, expertise, data, and actionable intelligence to assist customers, clients and care providers throughout this time. The situation surrounding COVID-19 remains fluid with continued uncertainty and a wide range of potential outcomes. We continue to actively manage our response and assess impacts to our financial position and operating results, as well as mitigate adverse developments in our business. Further discussion of the potential impacts on our business from the COVID-19 pandemic is provided under Part I, Item 1A – Risk Factors of the Form 10-K filed on March 14, 2022.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2022
BASIS OF PRESENTATION
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, and majority-owned entities. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments that might become necessary should the Company be unable to continue as a going concern. All significant intercompany balances and transactions have been eliminated in consolidation. For entities in which management has determined the Company does not have a controlling financial interest but has varying degrees of influence regarding operating policies of that entity, the Company’s investment is accounted for using the equity method of accounting. Accounting Policies There have been no changes to the Company’s significant accounting policies or recent accounting pronouncements during the nine months ended September 30, 2022, as compared to the significant accounting policies disclosed in the 10-K for the year ended December 31, 2021 as filed on March 14, 2022. Common Stock Reverse Split During September 2021, the Company effectuated a five ​ Reclassifications ​ Certain amounts for the three and nine months ended September 30, 2021 have been reclassified to conform to the 2022 presentation.

REVENUE

REVENUE	9 Months Ended
	Sep. 30, 2022
REVENUE
REVENUE	3. REVENUE The Company disaggregates revenue from contracts with customers by revenue stream as this depicts the nature, amount, timing and uncertainty of its revenue and cash flows as affected by economic factors. Commercial insurance consists of neuromonitoring cases whereby a patient has healthcare insurance. Facility billing consists of neuromonitoring cases whereby the company has an agreement with the facility for services. In these cases, the hospital’s patient may be uninsured or have government insurance. ​ The Company’s revenue disaggregated by payor is as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2022 2021 ​ 2022 2021 ​ ​ ​ ​ ​ ​ Commercial insurance $ 4,283 ​ $ 6,164 ​ $ 6,801 ​ $ 12,507 Facility billing ​ 1,185 ​ ​ 995 ​ ​ 3,457 ​ ​ 2,846 Managed service agreements ​ 400 ​ ​ 965 ​ ​ 1,247 ​ ​ 3,024 Other 336 ​ 422 ​ 1,045 ​ 1,156 Total $ 6,204 ​ $ 8,546 ​ $ 12,550 ​ $ 19,533 ​ Accounts Receivable A summary of the accounts receivable, net, by revenue stream is as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ December 31, ​ 2022 2021 ​ ​ ​ ​ ​ ​ ​ Technical service ​ $ 9,539 $ 18,904 Professional service ​ ​ 10,971 ​ ​ 8,209 Other ​ 350 ​ 697 Total accounts receivable, net ​ $ 20,860 ​ $ 27,810 ​ The concentration of accounts receivable, net, by payor as a percentage of total accounts receivable is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, ​ As of December 31, ​ ​ 2022 2021 ​ ​ ​ ​ ​ Commercial insurance ​ 91 % ​ 91 % Facility billing ​ 6 % ​ 2 % Other ​ 3 % ​ 7 % Total 100 % ​ 100 % ​

LEASES

LEASES	9 Months Ended
	Sep. 30, 2022
LEASES
LEASES	4. LEASES Under ASC 842, Leases Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term. As a practical expedient, the Company elected not to separate non-lease components for the corporate office facility (e.g., common-area maintenance costs) from lease components (e.g., fixed payments including rent) and instead to account for each separate lease component and its associated non-lease components as a single lease component Operating leases The Company leases corporate office facilities under an operating lease which expires October 31, 2025. The incremental borrowing rate for this lease was 10%. Finance leases The Company leases medical equipment under various financing leases with stated interest rates ranging from 5.2% — 13.4% per annum which expire at various dates through 2026. The condensed consolidated balance sheets include the following amounts for right of use (“ROU”) assets as of September 30, 2022 and December 31, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ December 31, ​ ​ 2022 2021 Operating $ 725 $ 956 Finance ​ 469 ​ 743 Total $ 1,194 $ 1,699 ​ Finance lease assets are reported net of accumulated amortization of $2.3 million and $2.0 million as of September 30, 2022 and December 31, 2021, respectively. ​ The following are the components of lease cost for operating and finance leases (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, ​ ​ 2022 2021 Lease cost: ​ ​ ​ ​ ​ ​ Operating leases: ​ ​ ​ ​ ​ ​ Amortization of ROU assets ​ $ 231 ​ $ 227 Interest on lease liabilities ​ ​ 68 ​ ​ — Total operating lease cost ​ ​ 299 ​ ​ 227 Finance leases: ​ ​ ​ ​ ​ ​ Amortization of ROU assets ​ ​ 353 ​ ​ 372 Interest on lease liabilities ​ ​ 64 ​ ​ 69 Total finance lease cost ​ ​ 417 ​ ​ 441 Total lease cost ​ $ 716 ​ $ 668 ​ ​ The following are the weighted average lease terms and discount rates for operating and finance leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ As of ​ ​ September 30, 2022 ​ September 30, 2021 ​ Weighted average remaining lease term (years): ​ ​ ​ ​ ​ Operating leases 3.0 ​ — ​ Finance leases 2.6 ​ 3.1 ​ Weighted average discount rate (%): ​ ​ ​ ​ ​ Operating leases 10.0 ​ — ​ Finance leases 7.8 ​ 8.1 ​ ​ The Company acquired ROU assets in exchange for lease liabilities of $79 thousand upon commencement of finance leases during the nine months ended September 30, 2022. Future minimum lease payments and related lease liabilities as of September 30, 2022 were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ ​ Operating ​ Finance ​ Lease ​ ​ Leases ​ Leases ​ Liabilities Remainder of 2022 ​ $ 84 ​ $ 165 ​ $ 249 2023 ​ 303 ​ 360 ​ 663 2024 ​ 328 ​ 268 ​ 596 2025 ​ ​ 279 ​ ​ 152 ​ ​ 431 2026 ​ ​ — ​ ​ 23 ​ ​ 23 Total lease payments ​ 994 ​ 968 ​ 1,962 Less: imputed interest ​ (145) ​ (93) ​ (238) Present value of lease liabilities ​ ​ 849 ​ ​ 875 ​ ​ 1,724 Less: current portion of lease liabilities ​ 231 ​ 391 ​ 622 Noncurrent lease liabilities ​ $ 618 ​ $ 484 ​ $ 1,102 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Note: Future minimum lease payments exclude short-term leases as well as payments to landlords for variable common area maintenance, insurance and real estate taxes.

DEBT

DEBT	9 Months Ended
	Sep. 30, 2022
DEBT
DEBT	5. DEBT The Company’s debt obligations are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ 2022 2021 Paycheck Protection Program loan ​ $ — ​ $ 1,687 ​ ​ ​ ​ ​ ​ ​ Face value of convertible debenture ​ 3,450 ​ 3,450 Less: principal converted to common shares ​ ​ (60) ​ ​ (60) Less: deemed fair value ascribed to conversion feature and warrants ​ (1,523) ​ (1,523) Plus: accretion of implied interest ​ 990 ​ ​ 705 Total convertible debt ​ 2,857 ​ 2,572 ​ ​ ​ ​ ​ ​ ​ Face value of Centurion debenture ​ ​ 11,000 ​ ​ 11,000 Less: deemed fair value ascribed to warrants ​ ​ (1,204) ​ ​ (1,204) Plus: accretion of implied interest ​ ​ 402 ​ ​ 176 Less: net debt issuance costs ​ ​ (427) ​ ​ (547) Total Centurion debt ​ 9,771 ​ 9,425 Total debt ​ 12,628 ​ 13,684 Less: current portion of debt ​ — ​ (515) Long-term debt ​ $ 12,628 ​ $ 13,169 ​ ​ ​ ​ During the nine months ended September 30, 2022, the Company recognized a gain of $1.7 million related to the January 2022 forgiveness of the balance of the Paycheck Protection Program loan. ​ The following table depicts accretion expense and interest expense (excluding debt issuance cost amortization) related to the Company’s debt obligations for the three and nine months ended September 30, 2022 and 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2022 2021 ​ 2022 2021 Accretion expense ​ ​ ​ ​ ​ Convertible debenture $ 95 ​ $ 95 ​ $ 285 ​ $ 285 Centurion debenture 75 ​ 76 ​ 226 ​ ​ 101 ​ $ 170 ​ $ 171 ​ $ 511 ​ $ 386 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest paid ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible debenture $ — ​ $ — ​ $ 221 ​ $ 220 Centurion debenture 324 ​ 190 ​ 872 ​ 236 ​ $ 324 ​ $ 190 ​ $ 1,093 ​ $ 456 ​ ​ ​ As of September 30, 2022, future minimum principal payments are summarized as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible ​ ​ ​ Debt Debenture Remainder of 2022 ​ $ — ​ $ — 2023 ​ 965 ​ — 2024 ​ 2,425 ​ — 2025 ​ — ​ 11,000 Total ​ ​ 3,390 ​ ​ 11,000 Less: fair value ascribed to conversion feature and warrants ​ (1,523) ​ (1,204) Plus: accretion and implied interest ​ 990 ​ 402 Less: net debt issuance costs ​ ​ — ​ ​ (427) ​ ​ $ 2,857 ​ $ 9,771 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Paycheck Protection Program ​ During March 2021, the Company received an unsecured loan under the United States Small Business Administration Paycheck Protection Program (“PPP”) in the amount of $1.7 million. Assure executed a PPP promissory note, with an original maturity date of February 25, 2026 (the “PPP Loan”). The PPP Loan carried an interest rate of 1.0% per annum, with principal and interest payments due on the first day of each month, with payments commencing on the earlier of: (i) the day the amount of loan forgiveness granted to Assure was remitted by the Small Business Administration to the Bank of Oklahoma; or (ii) 10 months after the end of the 24-week period following the grant of the Loan. Under the terms of the PPP Loan, all or a portion of the PPP Loan may be forgiven if the Company maintains its employment and compensation within certain parameters during the 24-week period following the loan origination date and the proceeds of the PPP Loan were spent on payroll costs, rent or lease agreements dated before February 15, 2020, and utility payments arising under service agreements dated before February 15, 2020. The Company submitted its application for forgiveness of the PPP Loan during the fourth quarter of 2021 and in January 2022, the Company received forgiveness of the $1.7 million PPP Loan resulting in no balance due. Convertible Debt From November 2019 through May 2020, the Company closed multiple non-brokered private placements of convertible debenture units (“CD Unit”) for gross proceeds of $3.5 million. Each CD Unit was offered at a price of $1. Each CD Unit included, among other things, one common share purchase warrant that allows the holder to purchase shares of the Company’s common stock at prices ranging from $5.00 to $9.50 per share for a period of three years and the right to convert the CD Unit into shares of the Company’s common stock at a conversion prices ranging from $3.35 to $7.00 per share for a period of four years. The CD Units carry a 9% coupon rate. The fair value of the convertible debt was determined to be $1.7 million, the conversion feature $1.2 million and the warrants $600 thousand. The difference between the fair value of the debt of $1.7 million and the face value of convertible debt of $3.5 million will be accreted over the four-year life of the CD Units. Centurion Debt In June 2021, Assure issued a debenture to Centurion (the “Debenture”) with a maturity date of June 9, 2025 (the “Maturity Date”), in the principal amount of $11 million related to a credit facility comprised of a $6 million senior term loan (the “Senior Term Loan”), a $2 million senior revolving loan (the “Senior Revolving Loan”) and a $3 million senior term acquisition line (the “Senior Term Acquisition Line” and together with the Senior Term Loan and the Senior Revolving Loan, the “Credit Facility”). Additionally, the Company issued 275,000 warrants with an exercise price of $7.55 which expire on June 14, 2025. During November 2021, the Company and Centurion entered into an amendment to allow the Senior Short Term Acquisition Line to be utilized for organic growth and general working capital purposes. Under the terms and conditions of the debt arrangement, Centurion temporarily modified their debt covenant calculations to allow bad debt expense to be excluded for the first and second quarter of 2022. The Company’s was in compliance with the debt covenants as of September 30, 2022. The Credit Facility matures in June 2025 and bears interest at the rate of the greater of 9.50% or the Royal Bank of Canada Prime Rate plus 7.05% per annum. The fair value of the Debenture was determined to be $6.8 million and the warrants $1.2 million. The difference between the fair value of the debt of $6.8 million and the face value of the Debenture of $8.0 million will be accreted over the four-year term of the Debenture.

SHARE CAPITAL

SHARE CAPITAL	9 Months Ended
	Sep. 30, 2022
SHARE CAPITAL
SHARE CAPITAL	6. SHARE CAPITAL Common stock Common stock: 180,000,000 authorized; $0.001 par value. As of September 30, 2022, and December 31, 2021, there were 18,512,605 and 12,918,866 shares of common stock issued outstanding Reverse Share Split ​ During September 2021, the total number of shares of common stock authorized by the Company was reduced from 900,000,000 shares of common stock, par $0.001, to 180,000,000 shares of common stock, par $0.001, and the number of shares of common stock held by each stockholder of the Company were consolidated automatically into the number of shares of common stock equal to the number of issued and outstanding shares of common stock held by each such stockholder immediately prior to the reverse split divided by five five one ​ No fractional shares were issued in connection with the reverse split and all fractional shares were rounded up to the next whole share. ​ Additionally, all options, warrants and other convertible securities of the Company outstanding immediately prior to the reverse split were adjusted by dividing the number of shares of common stock into which the options, warrants and other convertible securities are exercisable or convertible by five five ​ All shares of common stock, options, warrants and other convertible securities and the corresponding price per share amounts have been presented to reflect the reverse split in all periods presented within this Form 10-Q. ​ 2022 Equity Financing ​ In August 2022, the Company completed an underwritten public offering with gross proceeds to the Company of approximately $6.2 million, before deducting underwriting discounts and other estimated expenses payable by the Company. Under the offering 5,576,087 common shares were issued at a price to the public of $1.12 per share. The Company is utilizing the net proceeds from this offering for general corporate purposes, including, but not limited to, repayment of indebtedness and increasing working capital expenditures. In addition, the Company granted the underwriter a 45-day ​ ​ Stock options In November 2021, the Company adopted and approved the 2021 Stock Incentive Plan and the 2021 Employee Stock Purchase Plan. The intent of the Company and the Board is that while the Amended 2020 Stock Option Plan and the 2020 Equity Incentive Plan will continue in existence in relation to the options and awards previously granted, the Board will not grant future options or awards thereunder. Instead, only the 2021 Stock Incentive Plan will be used for the grant of options and awards to eligible participants. ​ As of September 30, 2022, an aggregate of 1,870,000 shares of common stock were available for issuance under the 2021 Stock Option Plan. As of September 30, 2022, no transactions have occurred under the 2021 Employee Stock Purchase Plan. ​ Options under the Plan are granted from time to time at the discretion of the Board of Directors, with vesting periods and other terms as determined by the Board of Directors. ​ A summary of the stock option activity is presented below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ ​ Weighted Weighted ​ ​ ​ ​ ​ ​ Average ​ Average ​ ​ ​ ​ ​ Number of ​ Exercise ​ Remaining ​ Aggregate ​ ​ Shares Subject ​ Price Per ​ Contractual ​ Intrinsic Value ​ ​ to Options ​ Share ​ Life (in years) ​ (in thousands) Balance at December 31, 2021 1,204,233 ​ $ 5.56 ​ 3.6 ​ ​ ​ Options granted 130,000 ​ $ 5.16 ​ ​ ​ ​ ​ Options exercised (800) ​ $ 5.04 ​ ​ ​ ​ ​ Options canceled / expired (103,633) ​ $ 5.45 ​ ​ ​ ​ ​ Balance at September 30, 2022 1,229,800 ​ $ 4.98 3.0 $ 78 Vested and exercisable at September 30, 2022 882,542 ​ $ 5.14 2.3 $ 78 ​ The following table summarizes information about stock options outstanding and exercisable under the Company’s Stock Option Plan at September 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ Options Exercisable ​ Weighted ​ ​ ​ ​ ​ Average ​ Weighted ​ ​ ​ Weighted ​ ​ Remaining ​ Average ​ ​ ​ Average Number of ​ Contractual ​ Exercise Price ​ Number ​ Exercise Price Outstanding ​ Life (in years) ​ Per Share ​ Exercisable ​ Per Share 200,000 2.9 ​ $ 0.25 200,000 ​ $ 0.25 12,000 0.1 ​ $ 14.00 12,000 ​ $ 14.00 15,000 5.3 ​ $ 9.00 15,000 ​ $ 9.00 85,000 1.0 ​ $ 9.00 85,000 ​ $ 9.00 145,800 1.3 ​ $ 7.80 145,800 ​ $ 7.80 73,900 2.0 ​ $ 6.40 64,047 ​ $ 6.40 83,000 3.2 ​ $ 4.85 49,800 ​ $ 4.85 278,100 ​ 3.3 ​ $ 5.30 ​ 166,860 ​ $ 5.30 30,000 ​ 3.5 ​ $ 5.60 ​ 14,000 ​ $ 5.60 177,000 ​ 4.0 ​ $ 7.65 ​ 86,702 ​ $ 7.65 130,000 ​ 4.4 ​ $ 5.16 ​ 43,333 ​ $ 5.16 1,229,800 3.0 ​ $ 4.98 882,542 ​ $ 5.14 ​ The Company uses the Black-Scholes option pricing model to determine the estimated fair value of options. The fair value of each option grant is determined on the date of grant and the expense is recorded on a straight-line basis and is included as a component of general and administrative expense in the consolidated statements of operations. The assumptions used in the model include expected life, volatility, risk-free interest rate, dividend yield and forfeiture rate. The Company’s determination of these assumptions is outlined below. Expected life — Volatility — Risk-free interest rate — Dividend yield — Forfeiture rate — The following assumptions were used to value the awards granted during the nine months ended September 30, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, ​ ​ 2022 2021 ​ Expected life (in years) 5.0 5.0 ​ Risk-free interest rate 1.7 % 0.4 % Dividend yield — % — % Expected volatility 132 % 91 % ​ Stock-based compensation (benefit) expense for the three months ended September 30, 2022 and 2021 was $(108) thousand and $210 thousand, respectively. The stock-based compensation benefit for the three months ended September 30, 2022 was related to the reversal of expense due to stock option forfeitures and cancellations. Stock-based compensation expense for the nine months ended September 30, 2022 and 2021 was $464 thousand and $818 thousand, respectively. As of September 30, 2022, there was approximately $1.0 million of total unrecognized compensation cost related to 347,258 unvested stock options that is expected to be recognized over a weighted-average remaining vesting period of 3.2 years. ​ Derivative Liability ​ Stock options granted to consultants that have an exercise price that is stated in a different currency than the Company’s functional currency are treated as a liability and are revalued at the end of each reporting period for the term of the vesting period. Any change in the fair value of the stock option after the initial recognition is recorded as a component of other income, net in the consolidated statements of operations. These stock options expired, unexercised during October 2022. There were no stock options granted to consultants during the nine months ended September 30, 2022 and 2021 that required recurring fair value adjustments. ​ Changes in the Company’s stock option liability for the nine months ended September 30, 2022, was as follows (stated in thousands): ​ ​ ​ ​ ​ Balance at December 31, 2021 ​ $ 25 Gain on revaluation ​ 25 Balance at September 30, 2022 ​ $ — ​ The assumptions used for the Black-Scholes Option Pricing Model to revalue the stock options granted to consultants as of September 30, 2022 and December 31, 2021 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, ​ ​ As of December 31, ​ ​ ​ 2022 ​ 2021 ​ Risk free rate of return ​ 2.8 % ​ 0.4 % Expected life ​ 0.1 years ​ 1.8 years Expected volatility ​ 99 % ​ 186 % Expected dividend per share ​ nil ​ ​ nil ​ ​ Warrants As of September 30, 2022, and December 31, 2021, there were 3,940,006 warrants outstanding. ​ The following table summarizes warrants issued by transaction type: ​ ​ ​ ​ ​ Number of Warrants outstanding Convertible debt, warrants issued (Note 5) 380,874 Debenture, warrants issued (Note 5) ​ 275,000 July 2020 private placement, warrants issued (1) ​ 12,592 December 2020 equity financing warrants issued (1) ​ 3,271,540 Total warrant outstanding 3,940,006 ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) For a complete discussion of the warrants issued during July and December 2020, see Note 11 to the consolidated financial statement for the year ended December 31, 2021 as filed on Form 10-K on March 14, 2022.

(LOSS) INCOME PER SHARE

(LOSS) INCOME PER SHARE	9 Months Ended
	Sep. 30, 2022
(LOSS) INCOME PER SHARE
(LOSS) INCOME PER SHARE	7. (LOSS) INCOME PER SHARE The following table sets forth the computation of basic and fully diluted (loss) income per share for the three and nine months ended September 30, 2022 and 2021 (in thousands, except per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2022 2021 ​ 2022 2021 Net (loss) income ​ $ (1,433) ​ $ 91 ​ $ (8,618) ​ $ (2,447) Basic weighted average common stock outstanding ​ 15,220,948 ​ 11,838,032 ​ 13,686,686 ​ 11,528,371 Basic loss per share ​ $ (0.09) ​ $ 0.01 ​ $ (0.63) ​ $ (0.21) Net (loss) income ​ $ (1,433) ​ $ 91 ​ $ (8,618) ​ $ (2,447) Basic weighted average common shares outstanding ​ 15,220,948 ​ 11,838,032 ​ 13,686,686 ​ 11,528,371 Dilutive effect of stock options and warrants ​ — ​ 3,886,071 ​ — ​ — Dilutive weighted average common stock outstanding ​ 15,220,948 ​ 15,724,103 ​ 13,686,686 ​ 11,528,371 Diluted loss per share ​ $ (0.09) ​ $ 0.01 ​ $ (0.63) ​ $ (0.21) ​ Basic net income (loss) per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed using the treasury stock method to calculate the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential dilutive common shares include incremental common shares issuable upon the exercise of stock options, less shares from assumed proceeds. The assumed proceeds calculation includes actual proceeds to be received from the employee upon exercise and the average unrecognized stock compensation cost during the period Stock options to purchase 882,582 and 227,893 shares of common stock and warrants to purchase 3,940,006 and 462,068 shares of common stock were outstanding at September 30, 2022 and 2021 that were not included in the computation of diluted weighted average common stock outstanding because their effect would have been anti-dilutive.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2022
COMMITMENTS AND CONTINGENCIES.
COMMITMENTS AND CONTINGENCIES	8. COMMITMENTS AND CONTINGENCIES Indemnifications The Company is a party to a variety of agreements in the ordinary course of business under which it may be obligated to indemnify third parties with respect to certain matters. These obligations include, but are not limited to, contracts entered into with physicians where the Company agrees, under certain circumstances, to indemnify a third party, against losses arising from matters including but not limited to medical malpractice and other liability. The impact of any such future claims, if made, on future financial results is not subject to reasonable estimation because considerable uncertainty exists as to final outcome of these potential claims. As permitted under Nevada law, the Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company believes, given the absence of any such payments in the Company’s history, and the estimated low probability of such payments in the future, that the estimated fair value of these indemnification agreements is immaterial. In addition, the Company has directors’ and officers’ liability insurance coverage that is intended to reduce its financial exposure and may enable the Company to recover any payments, should they occur. In April 2022, the U.S. Department of Justice (“DOJ)” issued Civil Investigative Demands which seek information with respect to a civil investigation under the Anti-kickback Statute and the False Claims Act. We voluntarily contacted the DOJ offering to provide any materials needed in the investigation and to answer any questions. While our policy during the relevant time was to not seek payments from federal health care programs, the third-party billing company we used at that time submitted some claims to Medicare Advantage plans administered by commercial insurance companies. We have worked diligently to ensure that payments from Medicare Advantage plans have been returned to the commercial insurance companies and we believe we have returned substantially all such payments that we have discovered to date, totaling approximately $450 thousand. The DOJ has not made any allegations in the investigation, and we are currently unable to predict the eventual scope, ultimate timing, or outcome of this investigation. As a result, we are unable to estimate the amount or range of any potential loss, if any, arising from this investigation. ​ ​

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2022
SUBSEQUENT EVENTS.
SUBSEQUENT EVENTS	9. SUBSEQUENT EVENT ​ On October 11, 2022, Assure Holdings Corp. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Notice”). The Notice has no immediate effect on the continued listing status of the Company's Common Stock on The Nasdaq Capital Market, and, therefore, the Company's listing remains fully effective. The Company is provided a compliance period of 180 calendar days from the date of the Notice, or until April 10, 2023, to regain compliance with the minimum closing bid requirement, pursuant to Nasdaq Listing Rule 5810(c)(3)(A). If at any time before April 10, 2023, the closing bid price of the Company’s Common Stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, subject to Nasdaq’s discretion to extend this period pursuant to Nasdaq Listing Rule 5810(c)(3)(G) to 20 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement, and the matter would be resolved. If the Company does not regain compliance during the compliance period ending April 10, 2023, then Nasdaq may grant the Company a second 180 calendar day period to regain compliance, provided the Company meets the continued listing requirement for market value of publicly-held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum closing bid price requirement, and notifies Nasdaq of its intent to cure the deficiency. The Company will continue to monitor the closing bid price of its Common Stock and seek to regain compliance with all applicable Nasdaq requirements within the allotted compliance periods. If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's Common Stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the minimum bid price requirement during the 180-day compliance period, secure a second period of 180 days to regain compliance or maintain compliance with the other Nasdaq listing requirements. ​

REVENUE (Tables)

REVENUE (Tables)	9 Months Ended
	Sep. 30, 2022
REVENUE
Schedule of revenue disaggregated by payor	The Company’s revenue disaggregated by payor is as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2022 2021 ​ 2022 2021 ​ ​ ​ ​ ​ ​ Commercial insurance $ 4,283 ​ $ 6,164 ​ $ 6,801 ​ $ 12,507 Facility billing ​ 1,185 ​ ​ 995 ​ ​ 3,457 ​ ​ 2,846 Managed service agreements ​ 400 ​ ​ 965 ​ ​ 1,247 ​ ​ 3,024 Other 336 ​ 422 ​ 1,045 ​ 1,156 Total $ 6,204 ​ $ 8,546 ​ $ 12,550 ​ $ 19,533
Summary of accounts receivable activity	A summary of the accounts receivable, net, by revenue stream is as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ December 31, ​ 2022 2021 ​ ​ ​ ​ ​ ​ ​ Technical service ​ $ 9,539 $ 18,904 Professional service ​ ​ 10,971 ​ ​ 8,209 Other ​ 350 ​ 697 Total accounts receivable, net ​ $ 20,860 ​ $ 27,810
Schedule of concentration of accounts receivable by revenue stream as a percentage of total accounts receivable	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, ​ As of December 31, ​ ​ 2022 2021 ​ ​ ​ ​ ​ Commercial insurance ​ 91 % ​ 91 % Facility billing ​ 6 % ​ 2 % Other ​ 3 % ​ 7 % Total 100 % ​ 100 %

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2022
LEASES
Schedule of right of use assets	The condensed consolidated balance sheets include the following amounts for right of use (“ROU”) assets as of September 30, 2022 and December 31, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ December 31, ​ ​ 2022 2021 Operating $ 725 $ 956 Finance ​ 469 ​ 743 Total $ 1,194 $ 1,699
Schedule of components of lease cost	​ The following are the components of lease cost for operating and finance leases (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, ​ ​ 2022 2021 Lease cost: ​ ​ ​ ​ ​ ​ Operating leases: ​ ​ ​ ​ ​ ​ Amortization of ROU assets ​ $ 231 ​ $ 227 Interest on lease liabilities ​ ​ 68 ​ ​ — Total operating lease cost ​ ​ 299 ​ ​ 227 Finance leases: ​ ​ ​ ​ ​ ​ Amortization of ROU assets ​ ​ 353 ​ ​ 372 Interest on lease liabilities ​ ​ 64 ​ ​ 69 Total finance lease cost ​ ​ 417 ​ ​ 441 Total lease cost ​ $ 716 ​ $ 668
Schedule of weighted average lease terms and discount rates for operating and finance leases	​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ As of ​ ​ September 30, 2022 ​ September 30, 2021 ​ Weighted average remaining lease term (years): ​ ​ ​ ​ ​ Operating leases 3.0 ​ — ​ Finance leases 2.6 ​ 3.1 ​ Weighted average discount rate (%): ​ ​ ​ ​ ​ Operating leases 10.0 ​ — ​ Finance leases 7.8 ​ 8.1 ​
Schedule of future minimum lease payments and related lease liabilities of financing leases	Future minimum lease payments and related lease liabilities as of September 30, 2022 were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ ​ Operating ​ Finance ​ Lease ​ ​ Leases ​ Leases ​ Liabilities Remainder of 2022 ​ $ 84 ​ $ 165 ​ $ 249 2023 ​ 303 ​ 360 ​ 663 2024 ​ 328 ​ 268 ​ 596 2025 ​ ​ 279 ​ ​ 152 ​ ​ 431 2026 ​ ​ — ​ ​ 23 ​ ​ 23 Total lease payments ​ 994 ​ 968 ​ 1,962 Less: imputed interest ​ (145) ​ (93) ​ (238) Present value of lease liabilities ​ ​ 849 ​ ​ 875 ​ ​ 1,724 Less: current portion of lease liabilities ​ 231 ​ 391 ​ 622 Noncurrent lease liabilities ​ $ 618 ​ $ 484 ​ $ 1,102 ​

DEBT (Tables)

DEBT (Tables)	9 Months Ended
	Sep. 30, 2022
DEBT
Summary of debt obligations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ 2022 2021 Paycheck Protection Program loan ​ $ — ​ $ 1,687 ​ ​ ​ ​ ​ ​ ​ Face value of convertible debenture ​ 3,450 ​ 3,450 Less: principal converted to common shares ​ ​ (60) ​ ​ (60) Less: deemed fair value ascribed to conversion feature and warrants ​ (1,523) ​ (1,523) Plus: accretion of implied interest ​ 990 ​ ​ 705 Total convertible debt ​ 2,857 ​ 2,572 ​ ​ ​ ​ ​ ​ ​ Face value of Centurion debenture ​ ​ 11,000 ​ ​ 11,000 Less: deemed fair value ascribed to warrants ​ ​ (1,204) ​ ​ (1,204) Plus: accretion of implied interest ​ ​ 402 ​ ​ 176 Less: net debt issuance costs ​ ​ (427) ​ ​ (547) Total Centurion debt ​ 9,771 ​ 9,425 Total debt ​ 12,628 ​ 13,684 Less: current portion of debt ​ — ​ (515) Long-term debt ​ $ 12,628 ​ $ 13,169
Schedule of accretion expense and interest expense related to debt obligations	The following table depicts accretion expense and interest expense (excluding debt issuance cost amortization) related to the Company’s debt obligations for the three and nine months ended September 30, 2022 and 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2022 2021 ​ 2022 2021 Accretion expense ​ ​ ​ ​ ​ Convertible debenture $ 95 ​ $ 95 ​ $ 285 ​ $ 285 Centurion debenture 75 ​ 76 ​ 226 ​ ​ 101 ​ $ 170 ​ $ 171 ​ $ 511 ​ $ 386 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest paid ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible debenture $ — ​ $ — ​ $ 221 ​ $ 220 Centurion debenture 324 ​ 190 ​ 872 ​ 236 ​ $ 324 ​ $ 190 ​ $ 1,093 ​ $ 456
Schedule of future minimum principal payments	​ As of September 30, 2022, future minimum principal payments are summarized as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible ​ ​ ​ Debt Debenture Remainder of 2022 ​ $ — ​ $ — 2023 ​ 965 ​ — 2024 ​ 2,425 ​ — 2025 ​ — ​ 11,000 Total ​ ​ 3,390 ​ ​ 11,000 Less: fair value ascribed to conversion feature and warrants ​ (1,523) ​ (1,204) Plus: accretion and implied interest ​ 990 ​ 402 Less: net debt issuance costs ​ ​ — ​ ​ (427) ​ ​ $ 2,857 ​ $ 9,771

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	9 Months Ended
	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of stock options activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ ​ Weighted Weighted ​ ​ ​ ​ ​ ​ Average ​ Average ​ ​ ​ ​ ​ Number of ​ Exercise ​ Remaining ​ Aggregate ​ ​ Shares Subject ​ Price Per ​ Contractual ​ Intrinsic Value ​ ​ to Options ​ Share ​ Life (in years) ​ (in thousands) Balance at December 31, 2021 1,204,233 ​ $ 5.56 ​ 3.6 ​ ​ ​ Options granted 130,000 ​ $ 5.16 ​ ​ ​ ​ ​ Options exercised (800) ​ $ 5.04 ​ ​ ​ ​ ​ Options canceled / expired (103,633) ​ $ 5.45 ​ ​ ​ ​ ​ Balance at September 30, 2022 1,229,800 ​ $ 4.98 3.0 $ 78 Vested and exercisable at September 30, 2022 882,542 ​ $ 5.14 2.3 $ 78
Schedule of stock options outstanding and exercisable	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ Options Exercisable ​ Weighted ​ ​ ​ ​ ​ Average ​ Weighted ​ ​ ​ Weighted ​ ​ Remaining ​ Average ​ ​ ​ Average Number of ​ Contractual ​ Exercise Price ​ Number ​ Exercise Price Outstanding ​ Life (in years) ​ Per Share ​ Exercisable ​ Per Share 200,000 2.9 ​ $ 0.25 200,000 ​ $ 0.25 12,000 0.1 ​ $ 14.00 12,000 ​ $ 14.00 15,000 5.3 ​ $ 9.00 15,000 ​ $ 9.00 85,000 1.0 ​ $ 9.00 85,000 ​ $ 9.00 145,800 1.3 ​ $ 7.80 145,800 ​ $ 7.80 73,900 2.0 ​ $ 6.40 64,047 ​ $ 6.40 83,000 3.2 ​ $ 4.85 49,800 ​ $ 4.85 278,100 ​ 3.3 ​ $ 5.30 ​ 166,860 ​ $ 5.30 30,000 ​ 3.5 ​ $ 5.60 ​ 14,000 ​ $ 5.60 177,000 ​ 4.0 ​ $ 7.65 ​ 86,702 ​ $ 7.65 130,000 ​ 4.4 ​ $ 5.16 ​ 43,333 ​ $ 5.16 1,229,800 3.0 ​ $ 4.98 882,542 ​ $ 5.14
Schedule of assumptions were used to determine fair value of the awards	​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, ​ ​ 2022 2021 ​ Expected life (in years) 5.0 5.0 ​ Risk-free interest rate 1.7 % 0.4 % Dividend yield — % — % Expected volatility 132 % 91 %
Schedule of changes in stock option liability	Changes in the Company’s stock option liability for the nine months ended September 30, 2022, was as follows (stated in thousands): ​ ​ ​ ​ ​ Balance at December 31, 2021 ​ $ 25 Gain on revaluation ​ 25 Balance at September 30, 2022 ​ $ —
Schedule of warrants	​ ​ ​ ​ ​ Number of Warrants outstanding Convertible debt, warrants issued (Note 5) 380,874 Debenture, warrants issued (Note 5) ​ 275,000 July 2020 private placement, warrants issued (1) ​ 12,592 December 2020 equity financing warrants issued (1) ​ 3,271,540 Total warrant outstanding 3,940,006
Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of assumptions were used to determine fair value of the awards	​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, ​ ​ As of December 31, ​ ​ ​ 2022 ​ 2021 ​ Risk free rate of return ​ 2.8 % ​ 0.4 % Expected life ​ 0.1 years ​ 1.8 years Expected volatility ​ 99 % ​ 186 % Expected dividend per share ​ nil ​ ​ nil ​

(LOSS) INCOME PER SHARE (Tables

(LOSS) INCOME PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2022
(LOSS) INCOME PER SHARE
Schedule of computation of basic and fully diluted (loss) income per common share	The following table sets forth the computation of basic and fully diluted (loss) income per share for the three and nine months ended September 30, 2022 and 2021 (in thousands, except per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2022 2021 ​ 2022 2021 Net (loss) income ​ $ (1,433) ​ $ 91 ​ $ (8,618) ​ $ (2,447) Basic weighted average common stock outstanding ​ 15,220,948 ​ 11,838,032 ​ 13,686,686 ​ 11,528,371 Basic loss per share ​ $ (0.09) ​ $ 0.01 ​ $ (0.63) ​ $ (0.21) Net (loss) income ​ $ (1,433) ​ $ 91 ​ $ (8,618) ​ $ (2,447) Basic weighted average common shares outstanding ​ 15,220,948 ​ 11,838,032 ​ 13,686,686 ​ 11,528,371 Dilutive effect of stock options and warrants ​ — ​ 3,886,071 ​ — ​ — Dilutive weighted average common stock outstanding ​ 15,220,948 ​ 15,724,103 ​ 13,686,686 ​ 11,528,371 Diluted loss per share ​ $ (0.09) ​ $ 0.01 ​ $ (0.63) ​ $ (0.21)

NATURE OF OPERATIONS - Narrativ

NATURE OF OPERATIONS - Narrative (Details)	9 Months Ended
	Sep. 30, 2022 subsidiary
NATURE OF OPERATIONS
Number of indirect wholly-owned subsidiaries	2

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details)	1 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2022
BASIS OF PRESENTATION
Stockholders' Equity, Reverse Stock Split		During September 2021, the Company effectuated a five-for-one reverse stock split. All share, stock option and warrant information has been retroactively adjusted to reflect the stock split. See Note 6 for additional discussion.
Reverse stock split ratio	0.2

REVENUE - Disaggregation of Rev

REVENUE - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 6,204	$ 8,546	$ 12,550	$ 19,533
Commercial insurance
Disaggregation of Revenue [Line Items]
Revenue	4,283	6,164	6,801	12,507
Facility billing
Disaggregation of Revenue [Line Items]
Revenue	1,185	995	3,457	2,846
Managed service agreements
Disaggregation of Revenue [Line Items]
Revenue	400	965	1,247	3,024
Other revenue
Disaggregation of Revenue [Line Items]
Revenue	$ 336	$ 422	$ 1,045	$ 1,156

REVENUE - Accounts Receivable (

REVENUE - Accounts Receivable (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accounts receivable, net:
Total accounts receivable, net	$ 20,860	$ 27,810
Technical services
Accounts receivable, net:
Total accounts receivable, net	9,539	18,904
Professional services
Accounts receivable, net:
Total accounts receivable, net	10,971	8,209
Other.
Accounts receivable, net:
Total accounts receivable, net	$ 350	$ 697

REVENUE - Concentration of Acco

REVENUE - Concentration of Accounts Receivable (Details) - Accounts Receivable - Revenue Stream Concentration Risk	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Concentration of accounts receivable	100%	100%
Commercial insurance
Disaggregation of Revenue [Line Items]
Concentration of accounts receivable	91%	91%
Facility billing
Disaggregation of Revenue [Line Items]
Concentration of accounts receivable	6%	2%
Other revenue
Disaggregation of Revenue [Line Items]
Concentration of accounts receivable	3%	7%

LEASES - (Details)

LEASES - (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Incremental borrowing rate for operating lease	10%
Operating lease right of use asset, net	$ 725	$ 956
Finance lease right of use asset, net	469	743
Total right of use asset	1,194	1,699
Accumulated amortization of finance lease assets	$ 2,300	$ 2,000
Minimum
Lessee, Lease, Description [Line Items]
Rate of interest for finance lease	5.20%
Maximum
Lessee, Lease, Description [Line Items]
Rate of interest for finance lease	13.40%

LEASES - Components of Lease Co

LEASES - Components of Lease Cost (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Lease cost:
Amortization of ROU assets	$ 231	$ 227
Interest on lease liabilities	68
Total Operating lease cost	299	227
Amortization of ROU assets	353	372
Interest on lease liabilities	64	69
Total finance lease cost	417	441
Total lease cost	$ 716	$ 668

LEASES - Lease Terms and Discou

LEASES - Lease Terms and Discount Rates (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
LEASES
Weighted average remaining lease term: Operating leases (in years)	3 years	0 years
Weighted average remaining lease term: Financing leases (in years)	2 years 7 months 6 days	3 years 1 month 6 days
Weighted average discount rate: Operating leases (as a percent)	10%
Weighted average discount rate: Financing leases (as a percent)	7.80%	8.10%
ROU assets acquired in exchange for finance lease liabilities	$ 79

LEASES - Future Minimum Lease P

LEASES - Future Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Operating Leases
Remainder 2022	$ 84
2023	303
2024	328
2025	279
Total lease payments	994
Less: imputed interest	(145)
Present value of lease liabilities	849
Less: current portion of lease liabilities	231
Noncurrent lease liabilities	618
Finance Leases
Remainder 2022	165
2023	360
2024	268
2025	152
2026	23
Total lease payments	968
Less: imputed interest	(93)
Present value of lease liabilities	875
Less: current portion of lease liabilities	391
Noncurrent lease liabilities	484
Total Lease Liabilities
Remainder 2022	249
2023	663
2024	596
2025	431
2026	23
Total lease payments	1,962
Less: imputed interest	(238)
Present value of lease liabilities	1,724
Less: current portion of lease liabilities	622
Noncurrent lease liabilities	$ 1,102

DEBT - Debt Obligations (Detail

DEBT - Debt Obligations (Details) - USD ($)	1 Months Ended
	Jun. 30, 2021	Sep. 30, 2022	Dec. 31, 2021	Mar. 31, 2021
Debt
Total debt		$ 12,628,000	$ 13,684,000
Less: current portion of debt			(515,000)
Long-term debt		12,628,000	13,169,000
Paycheck Protection Program loan
Debt
Total		0	1,687,000
Face amount				$ 1,700,000
Bearing interest rate				1%
Convertible Debt
Debt
Total		3,390,000
Face amount		3,450,000	3,450,000
Less: principal converted to common shares		(60,000)	(60,000)
Less: deemed fair value ascribed to conversion feature and warrants		(1,523,000)	(1,523,000)
Plus: accretion of implied interest		990,000	705,000
Total debt		2,857,000	2,572,000
Centurion debenture
Debt
Total		11,000,000	11,000,000
Less: deemed fair value ascribed to conversion feature and warrants		(1,204,000)	(1,204,000)
Plus: accretion of implied interest		402,000	176,000
Less: net debt issuance costs		(427,000)	(547,000)
Total debt		$ 9,771,000	$ 9,425,000
Debenture with Maturity Date of June 9, 2025 | Credit Facility dated March 8, 2021
Debt
Bearing interest rate	9.50%
Royal Bank of Canada Prime Rate | Debenture with Maturity Date of June 9, 2025 | Credit Facility dated March 8, 2021
Debt
Variable rate	7.05%
Centurion Debt | Credit Facility dated March 8, 2021
Debt
Face amount	$ 8,000,000
Fair value of debt	$ 6,800,000
Term of debt	4 years
Debt Instrument, Covenant Compliance	Under the terms and conditions of the debt arrangement, Centurion temporarily modified their debt covenant calculations to allow bad debt expense to be excluded for the first and second quarter of 2022.  The Company’s was in compliance with the debt covenants as of September 30, 2022.
Centurion Debt | Senior Term Loan
Debt
Maximum borrowing capacity	$ 6,000,000
Number of warrants issued	275,000
Warrant exercise price (in dollars per share)	$ 7.55
Centurion Debt | Senior Revolving Loan
Debt
Maximum borrowing capacity	$ 2,000,000
Centurion Debt | Senior Term Acquisition Line
Debt
Maximum borrowing capacity	3,000,000
Centurion Debt | Debenture with Maturity Date of June 9, 2025
Debt
Face amount	11,000,000
Centurion Debt | Warrants | Credit Facility dated March 8, 2021
Debt
Fair value of debt	$ 1,200,000

DEBT - Accretion and interest e

DEBT - Accretion and interest expense, excluding debt issuance cost amortization (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Debt Instrument [Line Items]
Accretion expense	$ 170	$ 171	$ 511	$ 386
Interest paid	324	190	1,093	456
Convertible Debt
Debt Instrument [Line Items]
Accretion expense	95	95	285	285
Interest paid			221	220
Centurion debenture
Debt Instrument [Line Items]
Accretion expense	75	76	226	101
Interest paid	$ 324	$ 190	$ 872	$ 236

DEBT - Future Minimum Principal

DEBT - Future Minimum Principal Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Total debt	$ 12,628	$ 13,684
Convertible Debt
Debt Instrument [Line Items]
2023	965
2024	2,425
Total	3,390
Less: deemed fair value ascribed to conversion feature and warrants	(1,523)	(1,523)
Plus: accretion of implied interest	990	705
Total debt	2,857	$ 2,572
Debenture
Debt Instrument [Line Items]
2025	11,000
Total	11,000
Less: deemed fair value ascribed to conversion feature and warrants	(1,204)
Plus: accretion of implied interest	402
Less: net debt issuance costs	(427)
Total debt	$ 9,771

DEBT - Additional Information (

DEBT - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		9 Months Ended	14 Months Ended
	Jan. 31, 2022	May 31, 2020	Sep. 30, 2022	Dec. 31, 2020	Mar. 31, 2021
Non-brokered private placements of convertible debenture units ("CD Unit")
Debt
Proceeds from convertible debenture		$ 3,500		$ 3,500
Conversion price (in dollars per share)				$ 1
Interest rate				9%
Fair value of debt		1,700
Conversion feature		$ 1,200
Non-brokered private placements of convertible debenture units ("CD Unit") | First tranche
Debt
Term of debt				3 years
Non-brokered private placements of convertible debenture units ("CD Unit") | First tranche | Minimum
Debt
Conversion price (in dollars per share)				$ 5
Non-brokered private placements of convertible debenture units ("CD Unit") | First tranche | Maximum
Debt
Conversion price (in dollars per share)				$ 9.50
Non-brokered private placements of convertible debenture units ("CD Unit") | Second tranche
Debt
Term of debt		4 years		4 years
Non-brokered private placements of convertible debenture units ("CD Unit") | Second tranche | Minimum
Debt
Conversion price (in dollars per share)				$ 3.35
Non-brokered private placements of convertible debenture units ("CD Unit") | Second tranche | Maximum
Debt
Conversion price (in dollars per share)				$ 7
Non-brokered private placements of convertible debenture units ("CD Unit") | Warrants
Debt
Fair value of debt		$ 600
Paycheck Protection Program loan
Debt
Interest rate					1%
Debt forgiveness	$ 1,700		$ 1,700

SHARE CAPITAL - Narrative (Deta

SHARE CAPITAL - Narrative (Details)	1 Months Ended
	Sep. 30, 2021 $ / shares shares	Sep. 30, 2022 $ / shares shares	Dec. 31, 2021 $ / shares shares
SHARE CAPITAL
Common stock, shares authorized	900,000,000	180,000,000	180,000,000
Common stock, par value (in dollars per share) | $ / shares	$ 0.001	$ 0.001	$ 0.001
Common stock, shares issued		18,512,605	12,918,866
Common stock, shares outstanding		18,512,605	12,918,866
Common stock authorized after Reverse Share Split (shares)	180,000,000
Reverse stock split ratio	0.2
Fractional shares issued	0

SHARE CAPITAL - 2022 Equity Fin

SHARE CAPITAL - 2022 Equity Financing (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended
	Aug. 31, 2022	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from share issuance, net		$ 5,195	$ 832
2022 Equity Financing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from share issuance, net	$ 6,200
Share issuance, net (in shares)	5,576,087
Shares issue price	$ 1.12
Period to purchase additional shares	45 days
Percentage of additional shares issued	15%
2022 Equity Financing | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from share issuance, net	$ 7,200

SHARE CAPITAL - Stock Options (

SHARE CAPITAL - Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Consultants
Share Capital
Shares issued	0	0
Stock options
Share Capital
Shares available for issuance	1,870,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options at beginning of period (in shares)	1,204,233
Options granted (in shares)	130,000
Options exercised (in shares)	(800)
Options canceled / expired (in shares)	(103,633)
Options at end of period (in shares)	1,229,800		1,204,233
Options vested and exercisable as at end of the period	882,542
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Exercise Price at beginning of period (in dollars per share)	$ 5.56
Options granted (in dollars per share)	5.16
Options exercised (in dollars per share)	5.04
Options canceled / expired (in dollars per share)	5.45
Exercise Price at end of period (in dollars per share)	4.98		$ 5.56
Exercise Price vested and exercisable (in dollars per share)	$ 5.14
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Contractual Life (in years)	3 years		3 years 7 months 6 days
Weighted Average Remaining life vested and exercisable (in years)	2 years 3 months 18 days
Aggregate Intrinsic Value	$ 78
Aggregate Intrinsic Value vested and exercisable	$ 78

SHARE CAPITAL - Stock Options O

SHARE CAPITAL - Stock Options Outstanding and Exercisable (Details) - Stock options - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	1,229,800	1,204,233
Weighted Average Remaining Contractual Life (in years)	3 years	3 years 7 months 6 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 4.98	$ 5.56
Number Exercisable (in shares)	882,542
Weighted average exercise price of options exercisable (in dollars per share)	$ 5.14
$0.25 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	200,000
Weighted Average Remaining Contractual Life (in years)	2 years 10 months 24 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 0.25
Number Exercisable (in shares)	200,000
Weighted average exercise price of options exercisable (in dollars per share)	$ 0.25
$14.00 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	12,000
Weighted Average Remaining Contractual Life (in years)	1 month 6 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 14
Number Exercisable (in shares)	12,000
Weighted average exercise price of options exercisable (in dollars per share)	$ 14
$9.00 Exercise Price Per Share, group one
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	15,000
Weighted Average Remaining Contractual Life (in years)	5 years 3 months 18 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 9
Number Exercisable (in shares)	15,000
Weighted average exercise price of options exercisable (in dollars per share)	$ 9
$9.00 Exercise Price Per Share, group two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	85,000
Weighted Average Remaining Contractual Life (in years)	1 year
Weighted average exercise price of options outstanding (in dollars per share)	$ 9
Number Exercisable (in shares)	85,000
Weighted average exercise price of options exercisable (in dollars per share)	$ 9
$7.80 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	145,800
Weighted Average Remaining Contractual Life (in years)	1 year 3 months 18 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 7.80
Number Exercisable (in shares)	145,800
Weighted average exercise price of options exercisable (in dollars per share)	$ 7.80
$6.40 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	73,900
Weighted Average Remaining Contractual Life (in years)	2 years
Weighted average exercise price of options outstanding (in dollars per share)	$ 6.40
Number Exercisable (in shares)	64,047
Weighted average exercise price of options exercisable (in dollars per share)	$ 6.40
$4.85 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	83,000
Weighted Average Remaining Contractual Life (in years)	3 years 2 months 12 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 4.85
Number Exercisable (in shares)	49,800
Weighted average exercise price of options exercisable (in dollars per share)	$ 4.85
$5.30 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	278,100
Weighted Average Remaining Contractual Life (in years)	3 years 3 months 18 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 5.30
Number Exercisable (in shares)	166,860
Weighted average exercise price of options exercisable (in dollars per share)	$ 5.30
$5.60 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	30,000
Weighted Average Remaining Contractual Life (in years)	3 years 6 months
Weighted average exercise price of options outstanding (in dollars per share)	$ 5.60
Number Exercisable (in shares)	14,000
Weighted average exercise price of options exercisable (in dollars per share)	$ 5.60
$7.65 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	177,000
Weighted Average Remaining Contractual Life (in years)	4 years
Weighted average exercise price of options outstanding (in dollars per share)	$ 7.65
Number Exercisable (in shares)	86,702
Weighted average exercise price of options exercisable (in dollars per share)	$ 7.65
$5.16 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	130,000
Weighted Average Remaining Contractual Life (in years)	4 years 4 months 24 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 5.16
Number Exercisable (in shares)	43,333
Weighted average exercise price of options exercisable (in dollars per share)	$ 5.16
$5.14 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	1,229,800
Weighted Average Remaining Contractual Life (in years)	3 years
Weighted average exercise price of options outstanding (in dollars per share)	$ 4.98
Number Exercisable (in shares)	882,542
Weighted average exercise price of options exercisable (in dollars per share)	$ 5.14

SHARE CAPITAL - Assumptions Use

SHARE CAPITAL - Assumptions Used (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	5 years	5 years
Risk-free interest rate	1.70%	0.40%
Expected volatility	132%	91%
Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	1 month 6 days		1 year 9 months 18 days
Risk-free interest rate	2.80%		0.40%
Expected volatility	99%		186%
Expected dividend per share

SHARE CAPITAL - Stock-based Com

SHARE CAPITAL - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
SHARE CAPITAL
Stock-based compensation expense recognized	$ (108)	$ 210	$ 464	$ 818
Unrecognized compensation cost	$ 1,000		$ 1,000
Unvested stock options (in shares)	347,258		347,258
Weighted-average remaining vesting period			3 years 2 months 12 days

SHARE CAPITAL - Changes in Stoc

SHARE CAPITAL - Changes in Stock Option Liability (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Fair value of the stock option derivative liability
Balance at Beginning of period	$ 25
Gain on revaluation	$ 25

SHARE CAPITAL - Warrants (Detai

SHARE CAPITAL - Warrants (Details) - shares	Sep. 30, 2022	Dec. 31, 2021
Class of Warrant or Right [Line Items]
Number of warrants outstanding	3,940,006	3,940,006
Convertible Debt
Class of Warrant or Right [Line Items]
Number of warrants outstanding	380,874
Centurion debenture
Class of Warrant or Right [Line Items]
Number of warrants outstanding	275,000
July 2020 private placement
Class of Warrant or Right [Line Items]
Number of warrants outstanding	12,592
December 2020 equity financing
Class of Warrant or Right [Line Items]
Number of warrants outstanding	3,271,540

(LOSS) INCOME PER SHARE (Detail

(LOSS) INCOME PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net (loss) income	$ (1,433)	$ 91	$ (8,618)	$ (2,447)
Basic weighted average common stock outstanding	15,220,948	11,838,032	13,686,686	11,528,371
Basic loss per share	$ (0.09)	$ 0.01	$ (0.63)	$ (0.21)
Dilutive effect of stock options and warrants		3,886,071
Dilutive weighted average common stock outstanding	15,220,948	15,724,103	13,686,686	11,528,371
Diluted loss per share	$ (0.09)	$ 0.01	$ (0.63)	$ (0.21)
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted average common shares			882,582	227,893
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted average common shares			3,940,006	462,068

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details) $ in Thousands	Apr. 30, 2022 USD ($)
Indemnification Agreement
Commitments and Contingencies
Contingent liability	$ 450

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - $ / shares	Oct. 11, 2022	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Subsequent Event [Line Items]
Common stock, par value (in dollars per share)		$ 0.001	$ 0.001	$ 0.001
Subsequent Events
Subsequent Event [Line Items]
Common stock, par value (in dollars per share)	$ 0.001